By Katherine Hamilton
Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance.
The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low.
Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels.
While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said.
The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 20, 2024 14:44 ET (19:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。